Vital Therapies (VTL) Receives Average Rating of “Hold” from Brokerages

Vital Therapies (NASDAQ:VTL) has been assigned an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.

Separately, ValuEngine upgraded shares of Vital Therapies from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th.

Shares of NASDAQ:VTL traded down $0.08 during trading on Wednesday, hitting $11.25. 49,557 shares of the company’s stock were exchanged, compared to its average volume of 21,618,420. Vital Therapies has a 1-year low of $0.15 and a 1-year high of $9.75.

Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Monday, March 4th. The company reported ($0.06) EPS for the quarter.

Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Vital Therapies during the fourth quarter valued at approximately $37,000. Two Sigma Investments LP grew its holdings in Vital Therapies by 42.5% during the fourth quarter. Two Sigma Investments LP now owns 208,872 shares of the company’s stock valued at $39,000 after purchasing an additional 62,284 shares during the period. Bank of Montreal Can grew its holdings in Vital Therapies by 1,065.5% during the first quarter. Bank of Montreal Can now owns 5,000 shares of the company’s stock valued at $39,000 after purchasing an additional 4,571 shares during the period. Virtu Financial LLC grew its holdings in Vital Therapies by 120.3% during the fourth quarter. Virtu Financial LLC now owns 310,499 shares of the company’s stock valued at $58,000 after purchasing an additional 169,530 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Vital Therapies by 99.7% during the fourth quarter. Geode Capital Management LLC now owns 682,934 shares of the company’s stock valued at $127,000 after purchasing an additional 340,970 shares during the period. Institutional investors own 15.52% of the company’s stock.

About Vital Therapies

Vital Therapies, Inc, a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc in June 2003. Vital Therapies, Inc was founded in 2003 and is based in San Diego, California.

Read More: How does equity income fit into an investing strategy?

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.